Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1DFP

FACTOR D INHIBITED BY DIISOPROPYL FLUOROPHOSPHATE

Summary for 1DFP
Entry DOI10.2210/pdb1dfp/pdb
DescriptorFACTOR D, DIISOPROPYL PHOSPHONATE (3 entities in total)
Functional Keywordsserine protease, complement, factor d, hydrolase
Biological sourceHomo sapiens (human)
Cellular locationSecreted: P00746
Total number of polymer chains2
Total formula weight49209.92
Authors
Cole, L.B.,Chu, N.,Kilpatrick, J.M.,Volanakis, J.E.,Narayana, S.V.L.,Babu, Y.S. (deposition date: 1997-02-18, release date: 1998-02-25, Last modification date: 2024-11-20)
Primary citationCole, L.B.,Chu, N.,Kilpatrick, J.M.,Volanakis, J.E.,Narayana, S.V.,Babu, Y.S.
Structure of diisopropyl fluorophosphate-inhibited factor D.
Acta Crystallogr.,Sect.D, 53:143-150, 1997
Cited by
PubMed Abstract: Factor D (D) is a serine protease, crucial for the activation of the alternative complement pathway. Only a limited number of general serine protease inhibitors are known to inhibit D, most of which covalently bind to the serine hydroxyl of the catalytic triad. The structure of the first enzyme:inhibitor covalent adduct of D with diisopropyl fluorophosphate (DIP:D) to a resolution of 2.4 A is described. The inhibited enzyme is similar in overall structure to the native enzyme and to trypsin, yet exhibits notable differences in the active site. One region of the active site is conserved between D and trypsin with respect to amino-acid sequence and to conformation. Another reflects the amino-acid substitutions and conformational flexibility between these enzymes. The active-site histidine residue is observed in the gauche+ conformation, not the normal gauche- orientation seen in the classic catalytic triad arrangement required for enzymatic activity in serine proteases. Comparisons of the active sites between native D, the DIP:D adduct, and DIP-inhibited trypsin have provided fundamental insights currently being employed in the design of novel small-molecule pharmaceutical agents capable of modulating the alternative complement pathway.
PubMed: 15299948
DOI: 10.1107/S0907444996012991
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.4 Å)
Structure validation

237423

数据于2025-06-11公开中

PDB statisticsPDBj update infoContact PDBjnumon